The Cannabis Poland group, listed on NewConnect under the ticker CBD, has spent recent months consistently restructuring its portfolio of subsidiaries, and one of the most significant outcomes has been Certis Pharma sp. z o.o. – a uniquely positioned advisory firm specialising in the registration and regulatory compliance of pharmaceutical products, including medical cannabis.
Below is a complete picture of the company: its history, business model, current contracts, and its place within Cannabis Poland’s group strategy, set against the backdrop of the German, British and Australian markets.
Certis Pharma operates as a company offering „a safe route to the Polish pharmaceutical market” and „advisory services and registration under one roof”. Its team is made up of experts with more than twenty years’ experience in the pharmaceutical sector, drawn directly from industry, business and regulatory bodies, combining managerial, operational and regulatory expertise.
In practice, the company’s offering covers:
- implementing EU-GMP and EU-GDP standards at manufacturers of pharmaceutical raw materials, including non-fibrous cannabis,
- preparing registration dossiers and providing support with CP, DCP and MRP procedures, chiefly for Poland but also for Germany, the United Kingdom and other EU countries,
- quality audits of manufacturers of active substances, finished dosage forms, intermediate products and packaging,
- legal advisory on pharmaceutical law and regulations governing controlled substances,
- preparing business plans and financial forecasts for pharmaceutical companies, with particular emphasis on medical cannabis,
- designing pharmaceutical facilities and medical cannabis cultivation sites,
- sourcing clients interested in manufacturing partners’ services and providing support with market-entry strategies.
It is worth highlighting the composition of the expert team: the consultants include former officials of the Ministry of Health and the Chief Pharmaceutical Inspectorate, a Qualified Person (QP) with over twenty years’ experience in quality control and assurance, a lawyer with legislative drafting experience, and specialists from the Canadian industry — including former managers from MedReleaf and Aurora Cannabis, with proven experience implementing regulatory frameworks in the German (BfArM), British (MHRA) and Australian (TGA) markets. This blend of Polish administrative expertise with international Canadian and European know-how gives the company a genuine competitive edge in Poland’s still-immature cannabis advisory market.
As the second-largest medical cannabis market in Europe after Germany, Poland still lacks a sufficient number of domestic manufacturers holding GMP certification for pharmaceutical-grade cannabis raw material.
By combining Polish administrative expertise with a team well versed in the German, British and Australian markets, Certis Pharma supports and advises on projects to build medical cannabis production facilities to EU GMP 1 standard in Poland, while also guiding them through their subsequent growth, as well as client acquisition and account management.